Press Releases SynAct Pharma AB

Equities

SYNACT

SE0008241491

Market Closed - Nasdaq Stockholm Other stock markets 06:59:40 2024-04-30 am EDT			5-day change	1st Jan Change
6.84 ^SEK	-0.94%		-8.68%	-22.54%

Mar. 20	Sweden's SynAct Pharma Names New CEO	MT
Mar. 20	SynAct Pharma AB Elects New Board Members and Chairman at Extraordinary General Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Change in number of shares and votes in SynAct Pharma AB	Apr. 30	AQ
Notice of annual general meeting in SynAct Pharma AB	Apr. 30	AQ
Bulletin from the extraordinary general meeting of SynAct Pharma AB	Apr. 24	AQ
SynAct Pharma : Changes in SynAct Pharma's Nomination Committee ahead of the 2024 Annual General Meeting	Apr. 23	PU
Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting	Apr. 23	AQ
BioStock: Synact focuses on pushing forward rheumatoid arthritis project	Apr. 02	AQ
Notice of extraordinary general meeting in SynAct Pharma AB	Mar. 27	AQ
SynAct Pharma : has successfully completed the bookbuilding procedure - directed issues provide the company with a total of up to 49.2 MSEK.	Mar. 26	PU
SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK	Mar. 26	AQ
SynAct Pharma publishes Annual Report 2023	Mar. 26	AQ
SynAct Pharma AB (publ) ("SynAct") brings forward the publication of the annual report.	Mar. 25	AQ
SynAct Pharma comments on ownership changes among senior executives	Mar. 22	AQ
Synact's new CEO to BioStock: "I'm hitting the ground running"	Mar. 22	AQ
SynAct Pharma appoints Jeppe Øvlesen CEO	Mar. 20	AQ
Bulletin from the extraordinary general meeting of SynAct Pharma AB	Mar. 20	AQ
SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis	Mar. 10	AQ
Marina Bozilenko resigns from Board of Directors of SynAct Pharma	Feb. 27	AQ
SynAct Pharma AB (publ) (“SynAct”) today publishes the fourth quarter and annual results of 2023.	Feb. 23	AQ
SynAct Pharma publishes Q3 2023 interim report	Feb. 23	AQ
SynAct Pharma announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis	Feb. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SynAct Pharma AB

Equities

SYNACT

SE0008241491

Press Releases

Filters